Czerniecki BJ - Search Results

1

Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy.

Datta J, Berk E, Cintolo JA, Xu S, Roses RE, Czerniecki BJ. Datta J, et al. Among authors: czerniecki bj. Front Immunol. 2015 Jun 2;6:271. doi: 10.3389/fimmu.2015.00271. eCollection 2015. Front Immunol. 2015. PMID: 26082780 Free PMC article. Review.

2

Dendritic cell-based vaccines: barriers and opportunities.

Cintolo JA, Datta J, Mathew SJ, Czerniecki BJ. Cintolo JA, et al. Among authors: czerniecki bj. Future Oncol. 2012 Oct;8(10):1273-99. doi: 10.2217/fon.12.125. Future Oncol. 2012. PMID: 23130928 Free PMC article. Review.

3

Radiation as immunomodulator: implications for dendritic cell-based immunotherapy.

Roses RE, Datta J, Czerniecki BJ. Roses RE, et al. Among authors: czerniecki bj. Radiat Res. 2014 Aug;182(2):211-8. doi: 10.1667/RR13495.1. Epub 2014 Jul 3. Radiat Res. 2014. PMID: 24992163 Free PMC article. Review.

4

Optimizing dendritic cell-based approaches for cancer immunotherapy.

Datta J, Terhune JH, Lowenfeld L, Cintolo JA, Xu S, Roses RE, Czerniecki BJ. Datta J, et al. Among authors: czerniecki bj. Yale J Biol Med. 2014 Dec 12;87(4):491-518. eCollection 2014 Dec. Yale J Biol Med. 2014. PMID: 25506283 Free PMC article. Review.

5

Reengineering dendritic cell-based anti-cancer vaccines.

Koski GK, Cohen PA, Roses RE, Xu S, Czerniecki BJ. Koski GK, et al. Among authors: czerniecki bj. Immunol Rev. 2008 Apr;222:256-76. doi: 10.1111/j.1600-065X.2008.00617.x. Immunol Rev. 2008. PMID: 18364007 Review.

6

Differential production of IL-23 and IL-12 by myeloid-derived dendritic cells in response to TLR agonists.

Roses RE, Xu S, Xu M, Koldovsky U, Koski G, Czerniecki BJ. Roses RE, et al. Among authors: czerniecki bj. J Immunol. 2008 Oct 1;181(7):5120-7. doi: 10.4049/jimmunol.181.7.5120. J Immunol. 2008. PMID: 18802116

7

Asymptomatic changes in cardiac function can occur in ductal carcinoma-in-situ patients following treatment with HER-2/neu-pulsed dendritic cell vaccines.

Bahl S, Roses RE, Sharma A, Koldovsky U, Xu S, Weinstein S, Nisenbaum H, Fox K, Pasha T, Zhang P, Araujo L, Carver J, Czerniecki BJ. Bahl S, et al. Among authors: czerniecki bj. Am J Surg. 2009 Oct;198(4):488-94. doi: 10.1016/j.amjsurg.2009.06.014. Am J Surg. 2009. PMID: 19800453 Free PMC article.

8

Dendritic cells matured in the presence of TLR ligands overcome the immunosuppressive functions of regulatory T cells.

Berk E, Xu S, Czerniecki BJ. Berk E, et al. Among authors: czerniecki bj. Oncoimmunology. 2014 Jan 6;3:e27617. doi: 10.4161/onci.27617. eCollection 2014. Oncoimmunology. 2014. PMID: 25101219 Free PMC article.

9

CD4(+) T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8(+) T-cell Targeting of HER2/neu-Expressing Cancers.

Datta J, Xu S, Rosemblit C, Smith JB, Cintolo JA, Powell DJ Jr, Czerniecki BJ. Datta J, et al. Among authors: czerniecki bj. Cancer Immunol Res. 2015 May;3(5):455-63. doi: 10.1158/2326-6066.CIR-14-0208. Epub 2015 Mar 19. Cancer Immunol Res. 2015. PMID: 25791067 Free PMC article.

10

Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer.

Datta J, Berk E, Xu S, Fitzpatrick E, Rosemblit C, Lowenfeld L, Goodman N, Lewis DA, Zhang PJ, Fisher C, Roses RE, DeMichele A, Czerniecki BJ. Datta J, et al. Among authors: czerniecki bj. Breast Cancer Res. 2015 May 23;17(1):71. doi: 10.1186/s13058-015-0584-1. Breast Cancer Res. 2015. PMID: 25997452 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

200 results

Search Page